BRIEF published on 03/26/2026 at 22:24, 4 months 3 days ago DBV Technologies publishes its financial reports for 2025 AMF Financial Report DBV Technologies DRY VIASKIN®
BRIEF published on 03/26/2026 at 22:24, 4 months 3 days ago DBV Technologies Files 2025 Annual Report and Registration Document Financial Filing Annual Report Universal Registration Document Form 10-K DBV Technologies
PRESS RELEASE published on 03/26/2026 at 22:19, 4 months 3 days ago DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies files 2025 Annual Report on Form 10-K and Universal Registration Document with SEC and AMF. Company developing treatments for food allergies Annual Report Immunotherapy Form 10-K DBV Technologies Food Allergies
BRIEF published on 03/24/2026 at 21:35, 4 months 5 days ago DBV Technologies joins the CAC Mid 60 and SBF 120 indices Euronext Paris SBF 120 DBV Technologies CAC Mid 60 Inclusion Indices
BRIEF published on 03/24/2026 at 21:35, 4 months 5 days ago DBV Technologies Joins CAC Mid 60 and SBF 120 Indices Biopharmaceutical SBF 120 DBV Technologies CAC Mid 60 VIASKIN®
PRESS RELEASE published on 03/24/2026 at 21:30, 4 months 5 days ago DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review DBV Technologies joins CAC Mid 60 and SBF 120 indices on Euronext Paris, increasing visibility among investors. Company focuses on food allergy treatments using VIASKIN patch technology Euronext Paris SBF 120 DBV Technologies Food Allergies CAC Mid 60
BRIEF published on 03/04/2026 at 22:35, 4 months 25 days ago DBV Technologies Announces Participation in March Investor Conferences Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 03/04/2026 at 22:35, 4 months 25 days ago DBV Technologies will participate in investor conferences in March Investor Conferences Biopharmaceutical DBV Technologies March 2026 Citizens Life Sciences
PRESS RELEASE published on 03/04/2026 at 22:30, 4 months 25 days ago DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies to participate in upcoming investor conferences to present its late-stage biopharmaceutical developments for food allergies. Company uses proprietary VIASKIN patch technology for treatment Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 03/03/2026 at 22:35, 4 months 26 days ago DBV Technologies: Update on voting rights and shares Euronext Paris Share Capital Voting Rights Financial Regulations DBV Technologies
Published on 07/30/2026 at 04:10, 8 hours 30 minutes ago Pathfinder Ventures Announces Appointment of Mark Roseborough as Chief Executive Officer
Published on 07/30/2026 at 01:50, 10 hours 50 minutes ago Further Assays Infill Tunkillia Pit Extension Targets
Published on 07/30/2026 at 00:50, 11 hours 50 minutes ago Aton Announces Strategic Cooperation Relationship and Board Nominee
Published on 07/30/2026 at 00:00, 12 hours 40 minutes ago American Hotel Income Properties REIT LP to Host Second Quarter 2026 Results Conference Call on August 6, 2026
Published on 07/29/2026 at 23:01, 13 hours 39 minutes ago Blueberries Medical Announces C$1.1 Million Non-Brokered Private Placement
Published on 07/30/2026 at 12:37, 3 minutes ago Zentra Group plc: One Victoria - Contractor Administration and Termination
Published on 07/30/2026 at 12:35, 5 minutes ago JOHNNIE WALKER BLUE LABEL ANNOUNCES CALLUM TURNER AS GLOBAL AMBASSADOR
Published on 07/30/2026 at 11:08, 1 hour 32 minutes ago OHB Italia awarded contract for PRISMA Second Generation satellite
Published on 07/30/2026 at 09:07, 3 hours 33 minutes ago CNP Assicura, a subsidiary of CNP Assurances in Italy, announces an exclusive partnership with Fineco bank in the life insurance segment
Published on 07/30/2026 at 07:30, 5 hours 10 minutes ago Availability of the 2026 Interim Financial Report
Published on 07/30/2026 at 07:30, 5 hours 10 minutes ago Half-year 2026: Accor shows its agility in a challenging global environment
Published on 07/30/2026 at 07:00, 5 hours 40 minutes ago Mersen 2026 guidance raised after strong momentum in the first half
